Dataset: Expression data from cell lines originating from patients with multiple myeloma, plasmacytoma and diffuse large B-cell lymphoma
A predictive gene list for response to high dose melphalan therapy in patients diagnosed with multiple myeloma is generated by combining...
A predictive gene list for response to high dose melphalan therapy in patients diagnosed with multiple myeloma is generated by combining results from dose response experiments and microarray data using a B-cell line panel and the introduction of multivariate regression techniques. 18 malignant B-cell lines were analyzed by gene expression microarrays and screened for melphalan median dose dependent growth inhibition. Results are used to build a predictive gene list for response to high dose melphalan therapy in multiple myeloma.
- Species:
- human
- Samples:
- 18
- Source:
- E-GEOD-22759
- PubMed:
- 21559449
- Updated:
- Dec.12, 2014
- Registered:
- Sep.15, 2014
Factors:
(via ArrayExpress)
| Sample | CULTURING MEDIUM | CELL LINE |
|---|---|---|
| GSM562809 | RPMI-1640, 10% FBS | KMM-1 |
| GSM562810 | RPMI-1640, 10% FBS | KMS-11 |
| GSM5628 | RPMI-1640, 20% FBS | KMS-12-PE |
| GSM562812 | RPMI-1640, 20% FBS | KMS-12-BM |
| GSM562813 | IMDM, 10% FBS | lp-1 |
| GSM562814 | RPMI-1640, 10% FBS | MM1S |
| GSM562815 | RPMI-1640, 10% FBS | MOLP-2 |
| GSM562816 | RPMI-1640, 20% FBS | MOLP-8 |
| GSM562817 | RPMI-1640, 20% FBS, 2 mM L-glutamine, 1 mM sodium-pyrovate | NCI-H929 |
| GSM562818 | RPMI-1640, 10% FBS | OPM-2 |
| GSM562819 | RPMI-1640, 10% FBS | RPMI-8226 |
| GSM562820 | RPMI-1640, 10% FBS, 5 μM melphalan was added once a week | RPMI-8226 LR5 |
| GSM56282 | RPMI-1640, 10% FBS | U-266 |
| GSM562822 | RPMI-1640, 20% FBS | AMO-1 |
| GSM562823 | RPMI-1640, 20% FBS | DB |
| GSM562824 | RPMI-1640, 10% FBS | HT |
| GSM562825 | RPMI-1640, 10% FBS | OCI-Ly7 |
| GSM562826 | RPMI-1640, 10% FBS | SU-DHL-4 |